BioSpace News Archive

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update after the market close on Tuesday, March 23, 2021.

Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points include expansion of its cancer therapeutics through acquisition of license agreements and formation of synergistic partnerships and expansion of other niche therapeutics.

Lyell Immunopharma, Inc., an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, announced the appointment of Richard Sherry, M.D., as Senior Vice President, TIL Specialist and Clinical Lead.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints

Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,945,954 entitled “ARRDC1-Mediated Microvesicles (ARMMs) and Uses Thereof”.

Diverse Biotech, Inc. www.diversebiotech.com announced today that it has finalized a strategic transaction with Enveric Biosciences to license exclusive worldwide development and commercialization rights for five novel compounds to address the adverse side effects of cancer treatments.

Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society’s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the successful completion of a Phase 1 trial of PLN-1474, an oral, small-molecule selective inhibitor of the integrin α v β 1 in development for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis.

Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD), following its Health Canada approval in December 2020.

Citrine Medicine , a China -based rare disease therapeutics company, today announced that it will participate in three industry conferences in March, including a presentation at the 2021 WuXi Healthcare Forum, which will be held from March 15-18, 2021 .